ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

02 أغسطس 2022 16:02:00 بحسب Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

29 يوليو 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

11 يوليو 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 يوليو 2022 16:04:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

06 يونيو 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 يونيو 2022 16:16:00 بحسب Nasdaq GlobeNewswire

CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

25 مايو 2022 10:33:12 بحسب Nasdaq GlobeNewswire

Nationwide Survey of People with Seborrehic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

25 مايو 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update

05 مايو 2022 16:01:01 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 مايو 2022 08:00:04 بحسب Nasdaq GlobeNewswire

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

06 أبريل 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

28 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting

25 مارس 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study

25 مارس 2022 07:30:00 بحسب Nasdaq GlobeNewswire

National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments

22 مارس 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Arcutis to Host Investor Day on March 28

21 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 مارس 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

02 مارس 2022 05:30:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

22 فبراير 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis

01 فبراير 2022 08:00:01 بحسب Nasdaq GlobeNewswire